Vanguard Group Inc. raised its stake in shares of Exelixis by 12.8% in the first quarter. The 50 day moving average moved up $2.78 and the 200 day average was up $5.07.
Company shares are trading at $29.02 which is well above the 50 day moving average which is $26.24 and significantly above the 200 day moving average of $23.95. They now have a Dollars 30 price target on the stock.
Traders are more bearish on the company lately if you watch the change in short interest. The company experienced a rise in short interest between September 15, 2017 and September 29, 2017 of 8.25%. Short shares grew from 18,464,387 to 19,986,804 over that timeframe. Days to cover increased 1.0 to 5.0 and the percentage of shorted shares was 0.07% on September 29. Over the past twelve months, Exelixis, Inc. The Pres Prod Dev & Med Aff & CMO now owns $4,353,689 of the stock per the Form 4 SEC filing. Each unit, consisting of one share of common stock and a warrant to purchase 0.2 share of common stock will be sold for a purchase price of $3.00. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce.
Moving average convergence divergence (MACD) shows that the stock is on a PRICE RELATIVITY trend.
Here are a few substantial investment firms who have updated their positions. Rhenman & Partners Asset Management Ab augmented its holdings by buying 420,000 shares an increase of 66.7%. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 25,441,964 shares of the stock are valued at $629.94 million.
Shares of Exelixis, Inc. Cigna Investments Inc /new claims 9,641 shares valued at $233,000. That puts total institutional holdings at 236,108,468 shares, according to SEC filings. Acadian Asset Management LLC cut its ownership by selling 341,284 shares a decrease of 21.7% from 06/30/2017 to 09/30/2017.
As of quarter end Vigilant Capital Management, LLC had sold 1,000 shares trimming its holdings by 50.0%. The value of the position overall is up by 89.4%. BidaskClub upgraded shares of Exelixis from a buy rating to a strong-buy rating in a report on Friday, August 25th. The reason? The drug maker announced that the FDA has accepted Cabometyx's sNDA filing based on positive CABOSUN data in first line intermediate- and high-risk RCC.
In related news, Director Stelios Papadopoulos sold 72,210 shares of Exelixis stock in a transaction dated Monday, September 18th. The company has a market capitalization of $9.37 billion, a P/E ratio of 161.06 and a beta of 1.92. The biotechnology company reported $0.06 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.04 by $0.02. Breaking that down further, it has performed -3.70% for the week, -9.10% for the month, -5.53% over the last quarter, 16.30% for the past half-year and 107.89% for this previous year.
Current levels places Exelixis, Inc. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases.
"This is an important milestone for the cabozantinib development program; we are committed to studying cabozantinib in a range of tumor types as part of our mission to deliver medicines that improve treatment outcomes and give patients hope for the future".